Corrigendum to “Trends and variations in the treatment of stage I-III small cell lung cancer from 2008 to 2019: A nationwide population-based study from the Netherlands” [Lung Cancer 162C (2021) 61–70] (Lung Cancer (2021) 162 (61–70), (S0169500221005821), (10.1016/j.lungcan.2021.10.011))

Jelle Evers*, Lizza E.L. Hendriks, Katrien De Jaeger, Robin Wijsman, Dirk De Ruysscher, Chris Terhaard, Maurice van der Sangen, Sabine Siesling, Henk Struikmans, Mieke J. Aarts

*Corresponding author for this work

Research output: Contribution to journalComment/Letter to the editorAcademicpeer-review

5 Downloads (Pure)

Abstract

The authors would like to inform that in the original publication two rows stating ‘RT alone’ in Table 1 were included, whereas only the upper row regards ‘RT alone’ and the lower row regards ‘Chemotherapy alone’. Also, the percentages of patients receiving stereotactic body radiotherapy (SBRT) were calculated with the number of patients receiving any radiotherapy (excl. prophylactic cranial irradiation (PCI)) as denominator, which may be unclear in the original publication. The authors would like to apologise for any inconvenience caused.

Original languageEnglish
Pages (from-to)107-107
Number of pages1
JournalLung cancer
Volume167
Early online date29 Dec 2021
DOIs
Publication statusPublished - 1 May 2022

Fingerprint

Dive into the research topics of 'Corrigendum to “Trends and variations in the treatment of stage I-III small cell lung cancer from 2008 to 2019: A nationwide population-based study from the Netherlands” [Lung Cancer 162C (2021) 61–70] (Lung Cancer (2021) 162 (61–70), (S0169500221005821), (10.1016/j.lungcan.2021.10.011))'. Together they form a unique fingerprint.

Cite this